a

CyMedica Orthopedics enrolls 1st patient in clinical rehabilitation trial — 4 details

Written by  Adam Schrag | Tuesday, 04 April 2017 20:08
Social sharing

Scottsdale, Ariz.-based Cymedica Orthopedics enrolled the first patient in a clinical trial to evaluate its e-vive muscle activation product.

Here are four things to know:

 

1. The system is aimed to improve patients' postoperative primary total knee arthroplasty rehabilitation and reduce associated postacute care costs.

 

2. CyMedica President and CEO Rob Morocco said, "This clinical trial will allow us to accelerate what we believe is an essential shift in the care model for total knee post-surgical rehabilitation."

 

3. The device addresses the issues associated with patients' lack of quadriceps strength after knee surgery.

 

4.  Patients often have to pay up to $4,200 to treat post-surgical muscle atrophy with rehabilitation and have a higher likelihood of readmissions.

 

More articles on devices:
Baxter highlights FLOSEAL hemostatic agent enhancements for spine, cardiac surgery: 5 highlights

Implanet intends to transfer share listing from Euronext to Alternext Paris: 5 key notes

Spinal implant 3D printing: 5 findings from 2 key cases

© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months